Genmab Achieves Milestone in Arzerra Collaboration
20-Apr-2010
- Denmark
“This milestone marks an important achievement; the first Genmab antibody to reach the market in Europe,” said Lisa N. Drakeman, Ph.D., Chief Executive Officer of Genmab.
Ofatumumab is a novel human monoclonal antibody with a unique mode of action. It targets a unique part of the CD20 molecule encompassing an epitope in the small loop. The CD20 molecule is a key target in CLL therapy, because it is expressed in most B cell malignancies.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.